found that Erastin and sorafenib-treated HCC cell lines exhibited inhibitory growth under Nrf2 inhibition, where Nrf2 is a negative ferroptosis regulator (Sun et al., 2016a). Here, NFE2L2 is linked to hepatocellular carcinoma.